|
1
|
Goff BA, Mandel LS, Drescher CW, et al:
Development of an ovarian cancer symptom index: possibilities for
earlier detection. Cancer. 109:221–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shank JJ, Yang K, Ghannam J, et al:
Metformin targets ovarian cancer stem cells in vitro and in vivo.
Gynecol Oncol. 127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pils D, Bachmayr-Heyda A, Auer K, et al:
Cyclin E1 (CCNE1) as independent positive prognostic factor in
advanced stage serous ovarian cancer patients - a study of the
OVCAD consortium. Eur J Cancer. 50:99–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Florea AM and Busselberg D: Cisplatin as
an anti-tumor drug: cellular mechanisms of activity, drug
resistance and induced side effects. Cancers. 3:1351–1371. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galluzzi L, Senovilla L, Vitale I, et al:
Molecular mechanisms of cisplatin resistance. Oncogene.
31:1869–1883. 2012. View Article : Google Scholar
|
|
7
|
Cho JM, Manandhar S, Lee HR, et al: Role
of the Nrf2- antioxidant system in cytotoxicity mediated by
anticancer cisplatin: implication to cancer cell resistance. Cancer
Lett. 260:96–108. 2008. View Article : Google Scholar
|
|
8
|
Hall MD, Handley MD and Gottesman MM: Is
resistance useless? Multidrug resistance and collateral
sensitivity. Trends Pharmacol Sci. 30:546–556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruiz S, Pergola PE, Zager RA, et al:
Targeting the transcription factor Nrf2 to ameliorate oxidative
stress and inflammation in chronic kidney disease. Kidney Int.
83:1029–1041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clarke HJ, Chambers JE, Liniker E, et al:
Endoplasmic reticulum stress in malignancy. Cancer Cell.
25:563–573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HJ, Lee JH, Kim SJ, et al: Roles of
NADPH oxidases in cisplatin-induced reactive oxygen species
generation and ototoxicity. J Neurosci. 30:3933–3946. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong YY, Chen HP, Tan BZ, et al:
Triptolide avoids cisplatin resistance and induces apoptosis via
the reactive oxygen species/nuclear factor-kappaB pathway in SKOV3
platinum-resistant human ovarian cancer cells. Oncol Lett.
6:1084–1092. 2013.
|
|
13
|
Taguchi K, Motohashi H and Yamamoto M:
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response
and cancer evolution. Genes Cells. 16:123–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang DD: The Nrf2-Keap1-ARE signaling
pathway: the regulation and dual function of Nrf2 in cancer.
Antioxid Redox Signal. 13:1623–1626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pi J, Zhang Q, Fu J, et al: ROS signaling,
oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol
Appl Pharmacol. 244:77–83. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moscat J, Diaz-Meco MT and Wooten MW:
Signal integration and diversification through the p62 scaffold
protein. Trends Biochem Sci. 32:95–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mazure NM and Pouyssegur J:
Hypoxia-induced autophagy: cell death or cell survival? Curr Opin
Cell Biol. 22:177–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu H, Su J, Xu Y, et al: p62/SQSTM1
involved in cisplatin resistance in human ovarian cancer cells by
clearing ubiquitinated proteins. Eur J Cancer. 47:1585–1594. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lau A, Zheng Y, Tao S, et al: Arsenic
inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a
p62-dependent manner. Mol Cell Biol. 33:2436–2446. 2013. View Article : Google Scholar
|
|
20
|
Lau A, Wang XJ, Zhao F, et al: A
noncanonical mechanism of Nrf2 activation by autophagy deficiency:
direct interaction between Keap1 and p62. Mol Cell Biol.
30:3275–3285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Y1, Parsons KK, Chi L, et al:
Glutathione S-transferase-microl regulates vascular smooth muscle
cell proliferation, migration, and oxidative stress. Hypertension.
54:1360–1368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma Q: Role of nrf2 in oxidative stress and
toxicity. Annu Rev Pharmacol Toxicol. 53:401–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sarkaria JN, Schwingler P, Schild SE, et
al: Phase I trial of sirolimus combined with radiation and
cisplatin in non-small cell lung cancer. J Thorac Oncol. 2:751–757.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agarwal R and Kaye SB: Ovarian cancer:
strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tummala MK and McGuire WP: Recurrent
ovarian cancer. Clin Adv Hematol Oncol. 3:723–736. 2005.
|
|
27
|
Kensler TW, Wakabayashi N and Biswal S:
Cell survival responses to environmental stresses via the
Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 47:89–116.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaramillo MC and Zhang DD: The emerging
role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev.
27:2179–2191. 2013. View Article : Google Scholar : PubMed/NCBI
|
